Hello Part-time Trader…👋

Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:

• Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.

• Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.

• Top Pre-Market Movers: Identify early winners poised for a strong market opening.

• Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.

• FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.

Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.

Happening Today

✓ 09:45 AM ET – S&P Global US Manufacturing PMI (Apr)

✓ 11:30 AM ET – S&P Global Services PMI (Apr)

✓ 11:30 AM ET – New Home Sales (Mar)

✓ 01:00 PM ET – 2-Year Note Auction

✓ 04:30 PM ET – API Weekly Crude Oil Stock

PREMARKET SNAPSHOT 📈

NASDAQ 100 Leads the Charge: Stock Futures Signal Potential Gains at Open

SECTOR SNAPSHOT ✨

Broader market sees modest gains, with Information Technology (+1.28%) leading the way.

Unusual Volume

📈 AGBA Group Holding Limited (AGBA) jumped 100.00% to $2.50 on a whopping 205.48 million shares traded.

📈 Investors went wild, sending NewGenIvf Group Ltd (NIVF) stock soaring 66.23% to $1.28 on a massive volume of 79.98 million shares after the company announced the signing non-binding term sheet for potential reverse merger with European Wellness Investment Holdings.

📈 Abnormal activity shook Moolec Science SA (MLEC), pushing it up 76.43% to $2.47 on a whopping 78.33 million shares traded. The company received USDA approval for Plant-Grown Animal Proteins.

📈 Matterport Inc (MTTR) stock recently closed 175.86% upper at $4.80 on substantial volume of 71.98 million shares. This unusual activity came after the company announced that it has entered into a definitive agreement with CoStar Group, Inc.

📈 SuperCom Ltd (SPCB) increase by 31.68% in a single trading session, with abnormally high trading volume of 70.11 million shares after reporting results for the twelve months and fourth quarter, ended December 31, 2023.

Premarket Movers

Cyngn Inc. (CYN) experiences a substantial 98.26% surge in pre-market trading after reporting that it has been chosen to supply its DriveMod Tuggers for industrial automation to John Deere's operation in Dubuque, Iowa.

ImmunityBio, Inc. (IBRX) sees a significant 19.64% increase, reaching a pre-market price of $5.91 after reporting that the U.S. Food and Drug Administration (FDA) has approved ANKTIVA.

Theriva Biologics, Inc. (TOVX) demonstrates a noteworthy 6.33% surge, with a pre-market price of $0.44. The company announced positive topline data from the investigator sponsored Phase 1 trial conducted by collaborators at Sant Joan de Déu-Barcelona Children’s Hospital (SJD).

Important FDA 

Recently Announced

On April 23, 2024, ImmunityBio, Inc (IBRX) celebrated a significant triumph as the FDA granted approval for their drug N-803, now commercially known as Anktiva. This approval, specifically for BCG-unresponsive non-muscle invasive bladder cancer, marks a pivotal moment in the fight against this challenging disease.

Johnson & Johnson (JNJ) achieved a notable milestone on April 5, 2024, with the FDA's approval of expanded use for their drug Carvykti in the treatment of relapsed or refractory multiple myeloma. This decision underscores JNJ's commitment to advancing therapies for complex conditions, providing renewed options for patients who have exhausted previous treatments.

Bristol-Myers Squibb Co. (BMY) received FDA approval on April 5, 2024, for Opdivo in combination with cisplatin-based chemotherapy, heralding a new era in the management of unresectable or metastatic urothelial carcinoma. This approval represents a significant advancement in frontline treatment options for patients facing this aggressive form of cancer.

Upcoming Announcements

On April 28, 2024, Aquestive Therapeutics Inc. (AQST) eagerly anticipates the FDA's decision on Libervant for the treatment of seizure clusters in pediatric patients aged between two and five years. This decision holds significant promise for improving the management of seizure disorders in young children, potentially offering a novel and effective treatment option.

XOMA Corporation (XOMA) awaits the FDA's decision on April 30, 2024, regarding tovorafenib for the treatment of relapsed or progressive pediatric low-grade glioma (pLGG). This decision represents a pivotal moment in the field of pediatric oncology, offering hope for patients and families confronting this challenging diagnosis.

On April 30, 2024, X4 Pharmaceuticals, Inc (XFOR) awaits the FDA's decision on Mavorixafor for the treatment of patients aged 12 and older with WHIM syndrome. This impending decision represents a significant milestone in the pursuit of effective therapies for rare immunodeficiency disorders.

Happy investing,

Maeve Grace
Editor In Chief
Premium Trade Alerts

Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.